Assessing the Real-World Effectiveness of Immunizations for Respiratory Syncytial Virus

Fatimah S Dawood; Amanda B Payne; Meredith L McMorrow

doi:10.1001/jama.2024.5859

Assessing the Real-World Effectiveness of Immunizations for Respiratory Syncytial Virus

JAMA. 2024 Jun 4;331(21):1799-1800. doi: 10.1001/jama.2024.5859.

Authors

Fatimah S Dawood¹, Amanda B Payne¹, Meredith L McMorrow¹

Affiliation

¹ Surveillance and Prevention Branch, Coronavirus and Other Respiratory Viruses Division, US Centers for Disease Control and Prevention, Atlanta, Georgia.

PMID: 38602685
DOI: 10.1001/jama.2024.5859

No abstract available

Plain language summary

This Viewpoint discusses recommendations from the US Centers for Disease Control and Prevention for newly licensed immunizations for respiratory syncytial virus in infants, children with high-risk conditions, and older adults.

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Child, Preschool
Humans
Immunization
Infant
Middle Aged
Respiratory Syncytial Virus Infections* / drug therapy
Respiratory Syncytial Virus Infections* / prevention & control
Respiratory Syncytial Virus Vaccines* / therapeutic use
Respiratory Syncytial Virus, Human
United States
Vaccine Efficacy

Substances

Respiratory Syncytial Virus Vaccines
nirsevimab
Antibodies, Monoclonal, Humanized